DYN
Dyne Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$24.28
−2.69%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 521.0K | 2.0M | 2.2M | 2.5M | — |
| Gross Profit | (521.0K) | (2.0M) | (2.2M) | (2.5M) | — |
| Operating Expenses | |||||
| R&D Expense | 445.7M | 398.3M | 281.4M | 210.8M | 142.8M |
| SG&A Expense | 91.3M | 69.9M | 62.5M | 31.4M | 28.2M |
| General & Admin Expense | 91.3M | 69.9M | 62.5M | 31.4M | 28.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (521.0K) | — | (2.2M) | (2.5M) | — |
| Total Operating Expenses | 536.4M | 466.1M | 341.6M | 239.7M | 171.0M |
| Cost and Expenses | 537.0M | 468.2M | 343.9M | 242.2M | 171.0M |
| Operating Income (EBIT) | (537.0M) | (468.2M) | (343.9M) | (242.2M) | (171.0M) |
| Non-Operating | |||||
| Interest Income | 32.7M | 29.9M | 26.9M | 7.6M | 2.9M |
| Interest Expense | 14.9M | 6.2M | — | — | 2.9M |
| Net Interest Income | 17.8M | 23.7M | 26.9M | 7.6M | — |
| Other Non-Op Income/Expense | 17.6M | 22.0M | 26.5M | 6.2M | 2.9M |
| Non-Operating Income (excl Interest) | (39.5M) | (28.2M) | (26.5M) | (6.2M) | (5.8M) |
| EBT (Pre-Tax Income) | (519.4M) | (446.2M) | (317.4M) | (235.9M) | (168.1M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (519.4M) | (446.2M) | (317.4M) | (235.9M) | (168.1M) |
| Earnings from Cont. Ops | (519.4M) | (446.2M) | (317.4M) | (235.9M) | (168.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (519.4M) | (446.2M) | (317.4M) | (235.9M) | (168.1M) |
| Per Share | |||||
| Basic EPS | ($3.33) | ($3.47) | ($3.37) | ($3.95) | ($3.23) |
| Diluted EPS | ($3.33) | ($3.47) | ($3.37) | ($3.95) | ($3.23) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 165.5M | 128.4M | 94.1M | 59.7M | 52.0M |
| Diluted Shares Outstanding | 165.5M | 128.4M | 94.1M | 59.7M | 52.0M |
| Profitability Metrics | |||||
| EBITDA | (495.3M) | (438.0M) | (315.2M) | (233.5M) | (163.5M) |
| D&A | 2.2M | 2.0M | 2.2M | 2.5M | 1.7M |
| EBIT | (497.5M) | (440.0M) | (317.4M) | (235.9M) | (165.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026